• “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置时时彩网络平台>技术资料首页>行业动态>公司动态>BioScale筹集2500万美元用于蛋白质分析技术的商业化与生产

    时时彩系统出租: BioScale筹集2500万美元用于蛋白质分析技术的商业化与生产

    BioScale2010年6月21日 9:52 点击:1903

    时时彩网络平台 www.qlgr.net

     

    BioScale筹集2500万美元用于蛋白质分析技术的商业化与生产

    公司开发、生产并销售ViBE™系统,以促进生物疗法的开发与生产

    马萨诸塞州剑桥--(BUSINESS WIRE)--开发、生产和推广新一代蛋白质分析技术的未公开上市生命科学公司BioScale Inc.今天宣布,该公司在其最近一轮的融资中筹得2500万美元。此轮融资由晨兴创投(Morningside Venture)领投,所筹得资金将被用于拓展ViBE蛋白质分析系统的生产运营和商业销售。此外,现有投资者New Science Ventures、WFD Ventures、F2 Ventures以及几名散户投资者也参与了该轮融资。

    BioScale创始人兼首席执行官Mark Lundstrom评论说:“晨兴创投是一家极具影响力的全球性生命科学投资商,我们很高兴通过它的加入来壮大我们的融资财团。晨兴创投的参与,加之我们现有投资者的大力支持,让BioScale为商业化推广阶段做好充分准备。此次融资将为把BioScale的ViBE产品系列推向市场提供资源,并让BioScale成为蛋白质分析技术领域的领导者。”

    晨兴创投的医学博士Isaac Cheng表示:“晨兴创投很高兴能在这一轮融资中与BioScale合作。我们很看好蛋白标志物的治疗与诊断潜力,并认为BioScale的新一代蛋白组学平台必将成为蛋白测定领域的领导者。随着BioScale在这一迅速拓展的市场中进入商业化阶段,我们对BioScale的发展前景充满信心,并期待着与BioScale经验丰富的管理团队以及现有投资者共同努力,从而在国内与国际实现增长。”

    关于BioScale

    BioScale是一家生命科学公司,开发、生产并推广新一代蛋白质分析技术,以加速生物与制药产品的药物发现、开发以及生产。BioScale的创新型ViBE系统能够对研究、临床、生物处理、患者现场护理以及个性化医药应用领域使用的复杂样品中的蛋白质进行超灵敏检测与定量分析。该公司成立于2002年,总部设在马萨诸塞州剑桥。垂询详情,请访问:www.bioscale.com。

    关于ViBE蛋白质分析系统

    BioScale的ViBE™系统通过对复杂生物混合物中的分析物进行高灵敏度繁殖检测与定量分析让新一代蛋白质分析成为可能。通过将简单的样品制备和微粒技术与新型检测及定量技术相结合,BioScale的通用ViBE系统在一系列应用中提供卓越的性能。ViBE系统让客户能够使用BioScale专有的AMMP™(声音隔膜微粒)操作原理技术快速制作并设定自己的试验。AMMP是一种无标签的非光学均质化验,非常适合在复杂的基质中进行。

    关于晨兴创投

    晨兴创投是一家多元化的投资集团,由香港的陈氏家族于1986年创立。该集团主要从事私募股权与风险资本投资。该集团在北美、欧洲以及亚太地区都有投资项目,并从1992年开始在中国大陆投资。晨兴创投曾是中国互联网行业最早的机构投资商之一。近几年来,该集团已经成为中国新兴生物技术领域的一名积极投资者。垂询详情,请登录:www.morningside.com。

    前瞻性陈述

    该新闻稿包含《1995年美国私人证券诉讼改革法案》(Private Securities Litigation Reform Act of 1995)所界定的某些前瞻性陈述。这些前瞻性陈述包括有关BioScale的未来预期、信念、意图、目标、战略、计划或未来前景的表述,其中包括该公司获得融资的能力、ViBE系统的开发与商业化、该公司蛋白质分析平台的前景、该公司用于开发与商业化蛋白质分析系统的战略以及该公司技术的广度与知识产权组合。前瞻性陈述可通过诸如“预计”、“相信”、“可能”、“可能会增加可能性”、“估计”、“预期”、“打算”、“计划”、“或许”、“应该”、“将要”、“将能够”、“预计会”、“期待”、“可能提供”和“将要”之类的术语或类似措辞、此类措辞的其他表述或此类措辞的否定表述来识别。此类前瞻性陈述涉及已知和未知风险、不确定性以及其他因素。由于这些风险、不确定性和因素,该公司的实际业绩可能会与前瞻性陈述中讨论或暗示的任何未来结果、业绩或成就产生显著差异。BioScale在本新闻稿中所提供的信息仅反映截至新闻稿发布之日的情况,并且无义务更新该新闻稿中的信息。

    免责声明:本公告之原文版本乃官方授权版本。译文仅供方便了解之用,烦请参照原文,原文版本乃唯一具法律效力之版本。

    Contacts

    BioScale Inc.
    投资者:
    Caitlin Fenn, 617-301-6145
    [email protected]
    媒体:
    Sharon Correia, 508-314-3155
    [email protected]
    www.bioscale.com



    BioScale . 75 Sydney Street . Cambridge, MA 02139 . 617-301-6100
    www.bioscale.com
    BIOSCALE RAISES $25 MILLION FOR COMMERCIALIZATION AND
    MANUFACTURING OF PROTEIN ANALYTICS TECHNOLOGY

    Company Developing, Manufacturing and Marketing ViBE™ Systems to Enhance
    Development and Production of Biotherapeutics
    CAMBRIDGE, MA June 14, 2010. BioScale Inc, a privately-held life science company
    that develops, manufactures and promotes a new generation of protein analytics
    technology, today announced that it has secured $25 million in its recent financing round.
    Led by new investor, Morningside Venture, this round will be used to expand manufacturing
    operations and commercial sales of the ViBE protein analytics systems. Also participating
    in the financing were existing investors New Science Ventures, WFD Ventures, F2
    Ventures, and several individual investors.
    "We are delighted to build our financing syndicate with the addition of Morningside - a
    powerful global life science investor,” Mark Lundstrom, Founder and CEO of BioScale
    commented. “Morningside's participation, along with the strong support of our existing
    investors, positions BioScale well for our commercialization phase. The financing will
    provide the resources to bring BioScale's ViBE product line into the market and establish
    BioScale as a leader in protein analytics technology."
    "Morningside is pleased to partner with BioScale in leading this financing round,” remarked
    Morningside’s Isaac Cheng, MD. “We are excited about the therapeutic and diagnostic
    potential of protein biomarkers, and feel BioScale’s next generation proteomics platform is
    well-positioned to become a leader in the protein measurement space. We are confident
    about BioScale’s prospects as it enters its commercialization phase in this rapidly
    expanding market, and look forward to working with BioScale’s experienced management
    team and existing investors toward achieving domestic and international growth.”
    About BioScale
    BioScale is a life science company that develops, manufactures and promotes a new
    generation of protein analytics technology to accelerate drug discovery, development and
    production of biological and pharmaceutical products. BioScale’s innovative ViBE systems
    enable ultra-sensitive detection and quantitation of proteins in complex samples used in
    research, clinical, bioprocessing, patient point-of-care and personalized medicine
    applications. Founded in 2002, the Company is headquartered in Cambridge, MA. For
    more information, visit www.bioscale.com.
    PRESS RELEASE
    BioScale . 75 Sydney Street . Cambridge, MA 02139 . 617-301-6100
    www.bioscale.com
    About ViBE™ Protein Analytics Systems
    BioScale’s ViBE™ systems enable a new generation of protein analytics by providing
    highly sensitive, reproducible detection and quantitation of analytes in complex biological
    mixtures. Integrating simple sample preparation and microparticle techniques, with novel
    detection and quantitation technology, BioScale’s versatile ViBE systems deliver high
    performance in a wide range of applications. The ViBE systems allow customers to rapidly
    create and configure their own assays using BioScale's proprietary principle of operation,
    AMMP™ (Acoustic Membrane MicroParticle) technology. AMMP is a label-free, nonoptical,
    homogeneous assay which is well-suited for operation in complex matrices.
    About Morningside
    Morningside is a diversified investment group founded in 1986 by the Chan family of Hong
    Kong. It is engaged primarily in private equity and venture capital investments. The group
    has investments in North America, Europe, across Asia-Pacific, and since 1992, in
    Mainland China. Morningside was one of the earliest institutional investors in China's
    internet industry and in recent years has been an active investor in China's emerging
    biotechnology sector. More information is available at www.morningside.com.
    Forward Looking Statements
    The foregoing release contains certain forward-looking statements within the meaning of
    the Private Securities Litigation Reform Act of 1995. Forward-looking statements include
    statements regarding BioScale’s future expectations, beliefs, intentions, goals, strategies,
    plans or prospects regarding the future, including the Company's ability to obtain financing,
    the development and commercialization of ViBE systems, the prospects of the Company's
    protein analytics platform, the Company's strategies to develop and commercialize protein
    analytics systems and the breadth of the Company's technologies and intellectual property
    portfolio. Forward-looking statements can be identified by terminology such as "anticipate,"
    "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is
    planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may
    provide," "would" or similar terms, variations of such terms or the negative of those terms.
    Such forward-looking statements involve known and unknown risks, uncertainties and other
    factors. As a result of such risks, uncertainties and factors, the Company's actual results
    may differ materially from any future results, performance or achievements discussed in or
    implied by the forward-looking statements contained herein. BioScale is providing the
    information in this press release as of this date and assumes no obligations to update the
    information in this press release.
    Investor Contact: Media Contact:
    Caitlin Fenn Sharon Correia
    617-301-6145 508-314-3155
    [email protected] [email protected]

    (来源: BioScale )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, 时时彩网络平台,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


  • “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 浙江快乐彩遗漏top10 bet365二八杠 手机qq欢乐斗地主 安徽25选5开奖结果查询 高频彩开奖助手app 甘肃11选5五十期走势图 今天上海快3开奖结果查询 竞彩推荐平台 南粤26选5最新开奖结果 hn8888vip好彩 七星彩开奖的规律 易胜博百家乐下载 北京赛车场 排列五走势图带连线500期内 欢乐升级甩拍牌视频